PTC Therapeutics Inc. (PTCT)
NASDAQ: PTCT · Pharmaceutical Preparations · Warren, NJ
Our rating: Positive
Positive reaffirmed at $59.97, high conviction, October 30, 2026.
Breaks if: The Positive call is wrong if annual revenue in the next reported fiscal year falls more than 15% below the current $1.7B — that is, lands below roughly $1.45B — or if free cash flow margin drops below 25% for two consecutive quarters (it currently sits above 40%). Either outcome would indicate the commercial surge is unwinding faster than the already-depressed multiple assumes, and the valuation cushion would narrow sharply. Conversely, the call would strengthen toward Conviction if a subsequent filing or disclosure reveals durable late-stage pipeline assets with near-term catalysts that could sustain or extend the current revenue base.
Key figures
| Market value | $4.7B |
|---|---|
| Revenue, last 12 months | $1.2B |
| Net income, last 12 months | −$106M |
| Free cash flow, last 12 months | $2M |
| Price to earnings | n/a |
| Free cash flow yield | 0.0% |
| Dividend yield | 0.0% |
| Operating margin | 12.8% |
| Return on equity | n/a |
| Beta to the S&P 500 | 0.98 |
| Volatility, annualized | 49.5% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $358M | 69.6% | $-0.62 | −$28M |
| June 30, 2026 | $361M | 101.5% | $0.92 | $127M |
| March 31, 2026 | $273M | −76.8% | $-0.03 | −$60M |
| December 31, 2025 | $165M | −22.7% | $-1.67 | −$37M |
| September 30, 2025 | $211M | 7.2% | $0.20 | −$70M |
| June 30, 2025 | $179M | −4.2% | $-0.83 | −$60M |
| March 31, 2025 | $1.2B | 459.7% | $10.04 | $868M |
| December 31, 2024 | $213M | −30.6% | $-0.85 | −$34M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.19B: Claude 78%, Gemini 95%, Mistral 90%
- Diluted earnings per share are above zero: Claude 35%, Gemini 45%, Mistral 45%
- Free cash flow for the quarter is above zero: Claude 35%, Gemini 40%, Mistral 35%
10 ledger entries and 45 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.